APHP, Biologie Cellulaire, Hôpital Saint-Louis, Paris, France.
France Intergroupe Syndromes Myéloprolifératifs (FIM), Paris, France.
Br J Haematol. 2022 Feb;196(3):676-680. doi: 10.1111/bjh.17848. Epub 2021 Sep 25.
We assessed the diagnostic performances of erythropoietin and JAK2 mutations in 1,090 patients with suspected polycythemia who were referred for red cell mass (RCM) measurement. In patients with a high haematocrit and/or haemoglobin level, a low erythropoietin level (<=3·3 mUI/ml) and JAK2 mutation showed comparable positive predictive value (PPV) for true polycythemia (RCM>=125%), 92·1% and 90% respectively. A very-low erythropoietin level (<=1·99 mUI/ml) had a PPV of 100% for polycythemia vera (PV) diagnosis. We confirmed the correlations between RCM, erythropoietin and JAK2 variant allelic frequency in PV patients. This study prompts the need to revisit the role of EPO in PV diagnostic criteria.
我们评估了促红细胞生成素和 JAK2 突变在 1090 例疑似真性红细胞增多症患者中的诊断性能,这些患者被转介进行红细胞容量(RCM)测量。在血细胞比容和/或血红蛋白水平较高的患者中,低水平的促红细胞生成素(<=3.3 mUI/ml)和 JAK2 突变对真性红细胞增多症(RCM>=125%)的阳性预测值相当,分别为 92.1%和 90%。极低水平的促红细胞生成素(<=1.99 mUI/ml)对真性红细胞增多症(PV)的诊断具有 100%的阳性预测值。我们证实了 PV 患者 RCM、促红细胞生成素和 JAK2 变异等位基因频率之间的相关性。本研究提示有必要重新审视 EPO 在 PV 诊断标准中的作用。